Stock Price & Analysis

Based on the recent data and analysis, selling PYXS stock appears to be the prudent action. The company's recent portfolio prioritization to focus on PYX-201 while deprioritizing PYX-106 has created significant uncertainty. Despite analyst support from RBC Capital and HC Wainwright maintaining positive ratings, the stock's technical indicators show weakness with an RSI of 34.29, indicating bearish momentum.

The stock has faced significant volatility, and while management's decision to focus resources on PYX-201 may be strategically sound, the reduced pipeline optionality has led analysts to lower their price targets. RBC Capital recently reduced their target from $10 to $8, though maintaining an Outperform rating.

Based on the provided data and recent developments, here's the price prediction for PYXS stock in 2025:

PYXS stock is projected to reach $1.70-1.81 by mid-2025, driven by promising preliminary data from its lead program PYX-201 which showed 50% objective response rate in HNSCC patients. The company's strategic decision to deprioritize PYX-106 to focus resources on PYX-201, along with sufficient cash runway into second half of 2026, supports this upward trajectory. However, current technical indicators showing RSI at 34.29 and negative MACD suggest near-term consolidation before the upward move.

The S1 support level for PYXS Stock is $1.42 ,The R1 resistant level for PYXS Stock is $1.64.

As of the end of day on 2025-02-10, the price of PYXS Stock was $1.32.

The target price for PYXS Stock according to analyst rating is 9.60, with the highest price target at 13.00 and the lowest at 5.00. Analysts have a Strong Buy rating on PYXS Stock overall.

The market cap of PYXS is $79.1M.

Based on the provided data, PYXS appears significantly overvalued considering several key factors:

Recent Performance and Strategic Shifts The company recently deprioritized its second clinical program PYX-106 to focus resources on advancing its lead program PYX-201. While this strategic decision aims to optimize resource allocation, it reduces pipeline diversity and increases risk concentration.

Financial Health Concerns The company shows deteriorating financial metrics with:

• Widening net losses: Q3 2024 net loss of -$21.2M compared to -$17.3M in Q2
• Declining revenue: No revenue in Q2 and Q3 2024 after $16.1M in Q1
• Worsening net margin: Dropped from -127.3% in Q2 to -258.6% in Q3 2024

Institutional Ownership Changes Major institutional holders have maintained or reduced positions:

• Pfizer holds 10.02% (unchanged)
• Deep Track Capital reduced to 7.10% from 7.20%
• Limited new institutional interest

Analyst Sentiment Recent analyst actions indicate caution:

• William Blair downgraded to Hold from Buy in November 2024
• RBC Capital lowered price target from $10 to $8 in December 2024
• HC Wainwright reduced target from $7 to $5 while maintaining Strong Buy

The stock appears overvalued given its:

1. Deteriorating financials
2. High cash burn rate
3. Reduced pipeline diversity
4. Mixed analyst sentiment
5. Limited institutional buying interest

Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes PYX-201, PYX-106 and PYX-107. PYX-201, an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-107 is a CD40 agonist antibody designed to maximize its agonistic properties. Its therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its ADC and immuno-oncology (IO) programs target a range of solid tumors resistant to current standards of care.

Based on the available data and market analysis, PYXS stock is projected to reach $3.50-4.00 by 2030, driven by the success potential of their lead program PYX-201 which showed promising preliminary results in treating solid tumors. The company's strategic focus on PYX-201 and sufficient cash runway into 2026 provides a foundation for long-term growth, though the recent deprioritization of PYX-106 indicates a more concentrated development approach. Technical indicators showing current RSI at 34.29 and negative MACD suggest near-term price consolidation, but the long-term outlook remains cautiously optimistic based on the company's pipeline development timeline and potential market opportunities in oncology treatment.

PYXS has a total of 50 employees.